• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For a lot of people suffering from depression, traditional therapies and medication are ineffective. The individual approach to treatment could be the answer.

Cue is an intervention platform that transforms sensors that are passively gathered from smartphones into personalized micro-interventions that improve mental health. We parsed the best treatment for severe depression-fit personalized ML models for each subject using Shapley values to identify their predictors of feature and reveal distinct features that deterministically change mood as time passes.

Predictors of Mood

Depression is the leading cause of mental illness around the world.1 Yet, only half of those affected receive treatment. To improve outcomes, healthcare professionals must be able identify and treat patients who are most likely to respond to specific treatments.

The ability to tailor depression treatments is one method to achieve this. By using sensors for mobile phones and an artificial intelligence voice assistant and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to predict which patients will benefit from which treatments. With two grants totaling over $10 million, they will use these techniques to determine biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

The majority of research done to so far has focused on sociodemographic and clinical characteristics. These include demographics such as age, gender, and education, as well as clinical aspects like symptom severity and comorbidities, as well as biological markers.

A few studies have utilized longitudinal data to determine mood among individuals. Few also take into account the fact that moods vary significantly between individuals. Therefore, it is crucial to create methods that allow the determination of different mood predictors for each person and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to recognize patterns of behavior and emotions that are unique to each person.

In addition to these modalities, the team developed a machine-learning algorithm to model the dynamic factors that determine a person's depressed mood. The algorithm blends the individual differences to produce a unique "digital genotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, which is a psychometrically validated scale for assessing severity of symptom. The correlation was low, however (Pearson r = 0,08, P-value adjusted by BH 3.55 10 03) and varied widely among individuals.

Predictors of symptoms

Depression is one of the most prevalent causes of disability1 yet it is often underdiagnosed and undertreated2. Depression disorders are rarely treated due to the stigma attached to them, as well as the lack of effective interventions.

To aid in the development of a personalized treatment, it is important to identify predictors of symptoms. However, the current methods for predicting symptoms rely on clinical interview, which has poor reliability and only detects a tiny number of symptoms associated with postpartum depression natural treatment - have a peek at this site -.2

Using machine learning to blend continuous digital behavioral phenotypes captured by smartphone sensors and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory the CAT-DI) along with other indicators of symptom severity has the potential to increase the accuracy of diagnostics and treatment efficacy for depression. These digital phenotypes allow continuous, high-resolution measurements. They also capture a wide range of unique behaviors and activity patterns that are difficult to record using interviews.

The study comprised University of California Los Angeles students with moderate to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or clinical care depending on the severity of their depression. Participants who scored a high on the CAT DI of 35 or 65 were assigned online support via the help of a coach. Those with a score 75 patients were referred for in-person psychotherapy.

At baseline, participants provided the answers to a series of questions concerning their personal demographics and psychosocial features. The questions included education, age, sex and gender, financial status, marital status, whether they were divorced or not, their current suicidal thoughts, intentions or attempts, as well as how often they drank. Participants also rated their level of depression severity on a scale ranging from 0-100 using the CAT-DI. The CAT-DI test was carried out every two weeks for those who received online support, and weekly for those who received in-person support.

Predictors of Treatment Response

Research is focused on individualized treatment for depression. Many studies are aimed at finding predictors that can help clinicians identify the most effective drugs for each person. Particularly, pharmacogenetics is able to identify genetic variants that influence how the body's metabolism reacts to antidepressants. This lets doctors choose the medications that are most likely to work for each patient, while minimizing the amount of time and effort required for trial-and error treatments and avoid any negative side consequences.

Another approach that is promising is to build models for prediction using multiple data sources, such as clinical information and neural imaging data. These models can be used to identify which variables are the most likely to predict a specific outcome, such as whether a medication will improve mood or symptoms. These models can also be used to predict the response of a patient to a treatment they are currently receiving, allowing doctors to maximize the effectiveness of treatment resistant depression currently being administered.

A new generation of studies employs machine learning techniques, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and increase predictive accuracy. These models have been proven to be effective in predicting the outcome of treatment, such as response to antidepressants. These methods are becoming more popular in psychiatry, and are likely to be the norm in future medical practice.

Research into the underlying causes of depression continues, in addition to predictive models based on ML. Recent research suggests that the disorder is associated with dysfunctions in specific neural circuits. This theory suggests that a individualized treatment for depression will be based on targeted therapies that restore normal function to these circuits.

One way to do this is through internet-delivered interventions that can provide a more individualized and tailored experience for patients. A study showed that a web-based program improved symptoms and provided a better quality of life for MDD patients. In addition, a controlled randomized trial of a personalized approach to treating depression showed sustained improvement and reduced side effects in a significant proportion of participants.

Predictors of Side Effects

In the treatment of antenatal depression treatment one of the most difficult aspects is predicting and determining the antidepressant that will cause no or minimal side effects. Many patients are prescribed a variety of medications before settling on a treatment that is safe and effective. Pharmacogenetics offers a fresh and exciting way to select antidepressant drugs that are more efficient and targeted.

A variety of predictors are available to determine the best antidepressant to prescribe, including gene variations, phenotypes of patients (e.g., sex or ethnicity) and the presence of comorbidities. However it is difficult to determine the most reliable and valid predictive factors for a specific treatment will probably require randomized controlled trials with much larger samples than those that are typically part of clinical trials. This is because the detection of moderators or interaction effects may be much more difficult in trials that only take into account a single episode of treatment per person instead of multiple episodes of treatment over time.

Furthermore the estimation of a patient's response to a particular medication will also likely require information about comorbidities and symptom profiles, in addition to the patient's previous experiences with the effectiveness and tolerability of the medication. There are currently only a few easily assessable sociodemographic variables and clinical variables appear to be reliable in predicting the response to MDD. These include gender, age, race/ethnicity as well as BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to untreatable depression treatment is still in its early stages and there are many hurdles to overcome. First, it is important to have a clear understanding and definition of the genetic mechanisms that cause depression, as well as an accurate definition of an accurate indicator of the response to treatment. Additionally, ethical issues, such as privacy and the responsible use of personal genetic information, must be carefully considered. The use of pharmacogenetics may, in the long run help reduce stigma around mental health treatment and improve treatment outcomes. As with all psychiatric approaches it is crucial to carefully consider and implement the plan. The best course of action is to offer patients a variety of effective depression medications and encourage them to talk freely with their doctors about their concerns and experiences.